Abstract
Objective Therapeutic efficacy of deep brain stimulation (DBS) in both established and emerging indications, is highly dependent on accurate lead placement and optimized clinical programming. The latter relies on clinicians’ experience to search among available sets of stimulation parameters and can be limited by the time constraints of clinical practice. Recent innovations in device technology have expanded the number of possible electrode configurations and parameter sets available to clinicians, amplifying the challenge of time constraints. We hypothesize that patient specific neuroimaging data which can effectively assist the clinical programming using automated algorithms.
Approach This paper introduces the DBS Illumina 3D algorithm as a tool which uses patient-specific imaging to find stimulation settings that optimizes activating a target area while minimizing the stimulation of areas outside the target that could result in unknown or undesired side effects. This approach utilizes preoperative neuroimaging data paired with the postoperative reconstruction of lead trajectory to search the available stimulation space and identify optimized stimulation parameters. We describe the application of this algorithm in three patients with treatment-resistant depression who underwent bilateral implantation of DBS in subcallosal cingulate cortex (SCC) and ventral capsule/ventral striatum (VC/VS) using tractography optimized targeting with an imaging defined target previously described.
Main results Compared to the stimulation settings selected by the clinicians (informed by anatomy), stimulation settings produced by the algorithm achieved similar or greater target coverage, while producing a significantly smaller stimulation area that spills outside the target (P=0.002).
Significance The DBS Illumina 3D algorithm is seamlessly integrated with the clinician programmer software and effectively and rapidly assists clinicians with the analysis of image based anatomy, and provides a starting point for the clinicians to search the highly complex stimulation parameter space and arrive at the stimulation settings that optimize activating a target area.
Clinical trial registration number: NCT 03437928
Competing Interest Statement
MM, RM and SC are employees of Boston Scientific Corporation. KC is an employee of Brainlab corporation. CCM is a paid consultant for Boston Scientific Neuromodulation, receives royalties from Hologram Consultants, Neuros Medical, Qr8 Health, and is a shareholder in the following companies: Hologram Consultants, Surgical Information Sciences, CereGate, Autonomic Technologies, Cardionomic, Enspire DBS. NP is a consultant for Abbott, Boston Scientific, Sensoria Therapeutic, and Second Sight Medical Products. SAS is a consultant for Boston Scientific, Zimmer Biomet, Neuropace, Abbott, and Koh Young.
Clinical Trial
NCT03437928
Funding Statement
Research reported in this publication was supported by the National Institute of Neurological Diseases and Stroke of the National Institutes of Health under Award Number UH3 NS103549.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board (IRB) of Baylor College of Medicine gave ethical approval for this work (Protocol Number H-43036).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Mahsa.Malekmohammadi{at}bsci.com, Richard.Mustakos{at}bsci.com, Stephen.Carcieri{at}bsci.com,
Sameer.Sheth{at}bcm.edu, bijanki{at}bcm.edu, meghan.robinson{at}bcm.edu, adkinson{at}bcm.edu, denise.oswalt{at}bcm.edu
nader.pouratian{at}utsouthwestern.edu
cameron.mcintyre{at}duke.edu
etsolaki{at}mednet.ucla.edu
kevin.chiu{at}brainlab.com
Data Availability
All data produced in the present study are available upon reasonable request to the authors
